Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
Main Author: | Akihisa Imagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Journal of Diabetes Investigation |
Online Access: | https://doi.org/10.1111/jdi.13450 |
Similar Items
-
Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
by: Wei Fang, et al.
Published: (2023-09-01) -
Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic
by: Hiroyuki Sano, et al.
Published: (2022-11-01) -
Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment
by: Satoko Hatayama, et al.
Published: (2022-08-01) -
A Case of Type 2 Diabetes Mellitus with Lung Cancer Suffered from Euglycemic Diabetic Ketosis Accompanied by Adrenal Insufficiency after Immune Checkpoint Inhibitors
by: Saeko Shibasaki, et al.
Published: (2024-01-01) -
Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient‐derived induced pluripotent stem cells for future research
by: Yoshiya Hosokawa, et al.
Published: (2019-09-01)